|
Allergy Therapeutics PLC on Thursday said its peanut allergy vaccine trial has entered the final treatment phase. The Sussex, England-based biotechnology company said healthy volunteers in the VLP Peanut Protect trial have progressed to the highest dose levels, with no safety signals observed. The final cohort of volunteers are now receiving subcutaneous doses of the peanut allergy vaccine candidate VLP Peanut beyond the expected dose level. The third of four planned cohorts is progressing through dose escalation, Allergy Therapeutics said. A new paper in the Journal of Allergy and Clinical Immunology also evaluates the tolerogenic properties and immunological reactivity of VLP Peanut. Allergy Therapeutics said it expects to announce initial topline data from the Protect trial in the summer. Shares in Allergy Therapeutics closed up 1.5% at 6.60 pence in London on Thursday. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
